Forefront Wealth Partners’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
Sell
-978
Closed -$227K 140
2025
Q3
$227K Sell
978
-438
-31% -$89.2K 0.06% 173
2025
Q2
$252K Buy
1,416
+42
+3% +$7.81K 0.17% 87
2025
Q1
$288K Sell
1,374
-42
-3% -$8.16K 0.2% 96
2024
Q4
$252K Buy
+1,416
New +$260K 0.19% 81

Other funds holding ABBV

Forefront Wealth Partners's ABBV Position: Q4 2025 in Review

Forefront Wealth Partners sold out of AbbVie (ABBV) in Q4 2025, closing a stake of 978 shares — an estimated $227K sold.

Forefront Wealth Partners first reported a position in ABBV in Q4 2024 and held it in 4 quarters. The position peaked at $288K in Q1 2025. 4,145 funds tracked by Wall St. Rank hold ABBV as of Q4 2025.

  • Forefront Wealth Partners reported no remaining AbbVie position as of Q4 2025 after selling out during the quarter.
  • Forefront Wealth Partners sold 978 AbbVie shares in Q4 2025, an estimated $227K.
  • Forefront Wealth Partners first reported a position in AbbVie in Q4 2024 and held it in 4 quarters.
  • Forefront Wealth Partners's AbbVie position peaked at $288K in Q1 2025.
  • 4,145 funds tracked by Wall St. Rank held AbbVie as of Q4 2025.

Based on Forefront Wealth Partners's 13F filing for Q4 2025, filed 6 Feb 2026.